U.S. lawmakers scale back bill targeting Chinese chipmaking

U.S. lawmakers scaled back the MATCH Act, removing several broad chip-equipment curbs, but the latest draft still adds a countrywide restriction on ASML's DUV immersion lithography machines and retains licensing requirements for servicing covered facilities. The bill would also bar foreign firms from selling to CXMT, YMTC, and SMIC for Washington-barred facilities and set a deadline for allied coordination before U.S. controls are imposed. The changes are less severe than the earlier version, but the legislation still signals tighter export controls across the semiconductor supply chain.

Analysis

The market should treat this as a repricing of policy optionality, not a clean negative for equipment vendors. The bill is materially less draconian than the first draft, which reduces the probability of an immediate demand shock, but the remaining countrywide restriction on ASML DUV immersion tools is still the most economically relevant piece because it targets the high-throughput node where Chinese logic and memory capacity additions are most sensitive.

Second-order, the bigger issue is not unit volume but mix and service revenue. Even if new tool shipments are partially insulated, forcing licensing for servicing covered fabs raises the probability of installed-base friction, lower uptime, and delayed upgrades — which can compound over multiple quarters into lower utilization and weaker aftermarket pull-through. That is more negative for ASML than for LRCX in the near term because ASML’s moat is concentrated in a smaller set of irreplaceable tools, while Lam has more cyclical exposure and a broader product basket.

The contrarian read is that a narrower bill may actually be more executable politically, which increases the chance it survives committee and becomes the baseline for broader allied coordination. If that happens, the real downside would not be the House vote itself but a follow-on Dutch/Japanese alignment process over the next 3-9 months, which could extend the restriction regime beyond China into third-country routing and gray-market servicing. That would pressure China-facing capex plans and likely compress multiples for suppliers with elevated China revenue exposure.

For ASML, the biggest tail risk is a policy cascade into service and spares, which would hit recurring revenue with a lag even if bookings hold up initially. For LRCX, the risk is more about sentiment contagion and a slower China replacement cycle than outright tool bans. The key catalyst window is the committee vote next week and any subsequent Dutch response over the next 1-2 quarters; if allied alignment stalls, the market will likely fade the headline risk quickly.

Key Decisions for Investors

• Short ASML into the committee vote / headline window, using a 1-3 month horizon; target downside is limited by the bill's dilution, but service-risk optionality justifies a tactical short or put spread if the stock rallies on 'less bad' framing.
• Relative-value pair: long LRCX / short ASML for 2-4 months, betting the market over-penalizes ASML’s higher policy sensitivity and underweights Lam’s broader diversification and faster China revenue reset.
• If owning ASML structurally, hedge with near-dated downside puts through the next 90 days; the risk/reward is skewed to event-driven gaps rather than gradual de-rating.
• Fade any knee-jerk selloff in LRCX only if management commentary confirms service continuity and China replacement demand remains stable; otherwise keep exposure underweight until allied implementation clarity improves.
• Set a trigger to add to ASML only if the bill stalls in committee or Dutch alignment appears unlikely; absent that, the asymmetry over the next quarter remains skewed negative.